EIC application for the development and commercialisation of InSingulo´s platform for drug discovery
| Reference number | |
| Coordinator | InSingulo AB |
| Funding from Vinnova | SEK 299 743 |
| Project duration | June 2024 - September 2024 |
| Status | Completed |
| Venture | Global cooperation 2024 |
| Call | Planning grant for international proposal 2024 |
Important results from the project
InSingulo used the support from Vinnova to write a competitive EIC Accelerator application. The funding gave us the advantage to use help from experts, which also improved the quality of the written documentation. As a result, InSingulo submitted a Step 1 application to the EIC Accelerator in July 2024. After receiving positive feedback, a high-quality Step 2 application was submitted in October 2024. The project’s goal was successfully achieved.
Expected long term effects
The EIC Accelerator funding will help us develop and launch our drug discovery tool faster. It will support our growth and prepare us for global production and sales. Pharma companies and research organizations will use our solution to develop new drugs, improving healthcare and patient care over time.
Approach and implementation
The 16-week project, conducted from 01/06/2024 to 30/09/2024, included three work packages: WP1 Detailed planning of specific work packages, WP2 Business plan and go-to-market strategy, and WP3 Strong EIC application. The work packages were executed by the InSingulo team (WP1, WP2) and supported by a qualified grant consultancy (WP3). All work packages were completed as planned, resulting in the submission of a new, complete application to the EIC Accelerator cut-off closed on October 3, 2024.